Rapport
Healthcare Access & Wellbeing
Developing therapies with neuroanatomically precise targeting.
Impact Rating
Developing therapies with neuroanatomically precise targeting.
Company Overview
Rapport Therapeutics aims to transform the treatment of neurological disorders through a precision medicine approach targeting disease-driving neurocircuits by using receptor-associated proteins (RAPs). These RAPs allow the identification of targeted small molecule drugs that have the potential to transform the treatment of neurological disorders, enabling doctors to develop precision medicines that modulate neurotransmitter receptors with greater efficacy and reduced side effects.
Rapport Therapeutics' Impact
Rapport Therapeutics aims to provide patients with improved neurological treatments, addressing the issues of suboptimal dosing, noncompliance, and discontinuation often associated with current treatments.
Core Mission and Values
Rapport describes their relationship characterised by understanding, communication, teamwork, and trust. They reflect those qualities in their daily work, operating as one committed team that captures the collective knowledge and experience of all members to improve their patients’ lives.
Current Investors
Investors include Fidelity Management & Research, Goldman Sachs Asset Management, Cormorant Asset Management, ARCH Venture Partners.
Leadership & Team
Abraham N. Ceesay
CEO
With extensive biopharmaceutical experience, served as President of Cerevel Therapeutics and CEO of Tiburio Therapeutics, specialising in rare neuroendocrine tumours. He is engaged in charitable and educational organisations.
David Bredt
Chief Scientific Officer
David, boasting 20+ years in neuroscience drug discovery, led ground-breaking research at Janssen as Global Head of Neuroscience Discovery (2011-2021) and held VP roles at Eli Lilly.
Chery Gault
COO
Cheryl Gault, with over 20 years of biopharma industry experience, has expertise in corporate strategy, portfolio planning, new product planning, marketing, sales, launch, and commercial strategy in various therapeutic areas. She served as Chief Operating Officer at Cyclerion Therapeutics and led the successful launch of LINZESS® at Ironwood.
Brad Galler
Chief Medical Officer
A seasoned drug development and medical affairs leader with over 20 years of experience, has led global teams focused on pain and epilepsy. He has published over 150 publications, and completed his medical doctorate and neurology residency at Albert Einstein College of Medicine.
How are Rapport planning to use funds raised?
Rapport Therapeutics has ongoing clinical programs in seizure and psychiatric disorders, and all the funds raised in the Series B funding stage will be going to support this work.
Research by: Bilal Ismail
Latest News in Life Sciences
05/23/25, 06:30 AM
Inventiva reports 2025 First Quarter Financial Information¹
Daix ( France ) , New York City ( New York, United States ) , May 23, 2025 - Inventiva ( Euronext Paris and Nasdaq: IVA ) ( the "Company" ) , a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated ...
Source: GlobeNewswire
Read more →
05/23/25, 06:30 AM
Inventiva reports 2025 First Quarter Financial Information¹ - Inventiva ( OTC:IVEVF ) , Inventiva ( NASDAQ:IVA )
Cash and cash equivalents at €67.9 million
Source: Benzinga
Read more →05/23/25, 06:00 AM
Results of the Votes of the Combined Shareholders' General Meeting of May 22, 2025 - Inventiva ( OTC:IVEVF ) , Inventiva ( NASDAQ:IVA )
Daix ( France ) , New York City ( New York, United States ) , May 23, 2025 - Inventiva ( Euronext Paris and Nasdaq: IVA ) ( the "Company" ) , a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated ...
Source: Benzinga
Read more →